15-Hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist

Molecular Pharmacology

Volumn 77, Issue 2, 2010, Pages 171-184

  Naruhn, Simone ^a   Meissner, Wolfgang ^a   Adhikary, Till ^a   Kaddatz, Kerstin ^a   Klein, Thomas ^b   Watzer, Bernhard ^a   Müller Brüsselbach, Sabine ^a   Müller, Rolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ANGPTL 4 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CHROMATIN; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; ENANTIOMER; FATTY ACID SYNTHESIS; FETUS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LUNG FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FIBROBLASTS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PPAR DELTA; PPAR-BETA; TRANS-ACTIVATORS;

EID: 74549222441     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060541     Document Type: Article

References (62)

1. Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, et al. (2007) Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A 104:12890-12895.
2. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, and Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99:303-308.
3. Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, and Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis 29:2406-2414.
4. Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin S, Gonzalez FJ, Ross AC, and Peters JM (2008) Ligand activation of peroxisome proliferatoractivated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes. Mol Pharmacol 74:1429-1442.
5. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, and Peters JM (2007) Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal 19:1163-1171.
6. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, and Peters JM (2006) The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal 18:9-20.
7. Chang C, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, and McDonnell DP (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol 19:8226-8239.
8. Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, and Spelsberg TC (2003) 15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. Int J Cancer 107:837-843.
9. Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, Ku CW, Goh YY, Wahli W, Michalik L, and Tan NS (2009) Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing. J Cell Biol 184:817-831.
10. Clària J, Lee MH, and Serhan CN (1996) Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 2:583-596.
11. Clària J and Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 92:9475-9479.
12. Desvergne B, Michalik L, and Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86:465-514.
13. Di-Poï N, Tan NS, Michalik L, Wahli W, and Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10:721-733.
14. Fauti T, Müller-Brüsselbach S, Kreutzer M, Rieck M, Meissner W, Rapp U, Schweer H, Kömhoff M, and Müller R (2006) Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta. FEBS J 273:170-179.
15. Forman BM, Chen J, and Evans RM (1996) The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 804:266-275.
16. Forman BM, Chen J, and Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312-4317.
17. Gehrke S, Jérôme V, and Müller R (2003) Chimeric transcriptional control units for improved liver-specific transgene expression. Gene 322:137-143.
18. Gilroy DW (2005) The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukot Essent Fatty Acids 73:203-210.
19. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, and Peters JM (2008) Quantitative expression patterns of peroxisome proliferator-activated receptorbeta/delta (PPARbeta/delta) protein in mice. Biochem Biophys Res Commun 371:456-461.
20. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, and DuBois RN (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 97:13275-13280.
21. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, and DuBois RN (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10:245-247.
22. Hatae T, Wada M, Yokoyama C, Shimonishi M, and Tanabe T (2001) Prostacyclindependent apoptosis mediated by PPAR delta. J Biol Chem 276:46260-46267.
23. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, and Glass CK (1999) Interleukin-4-dependent production of PPARgamma ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-382.
24. Jérôme V and Müller R (1998) Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther 9:2653-2659.
25. Kilgore KS and Billin AN (2008) PPARbeta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 9:463-469.
26. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, and Peters JM (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279:23719-23727.
27. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, and Peters JM (2006) PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 13:53-60.
28. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, and Curtiss LK (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302:453-457.
29. Li LP, Schlag PM, and Blankenstein T (1997) Transient expression of SV 40 large T antigen by Cre/LoxP-mediated site-specific deletion in primary human tumor cells. Hum Gene Ther 8:1695-1700.
30. Mahipal SV, Subhashini J, Reddy MC, Reddy MM, Anilkumar K, Roy KR, Reddy GV, and Reddanna P (2007) Effect of 15-lipoxygenase metabolites, 15-(S)-HPETE and 15-(S)-HETE on chronic myelogenous leukemia cell line K-562: reactive oxygen species (ROS) mediate caspase-dependent apoptosis. Biochem Pharmacol 74:202-214.
31. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, et al. (2004) The direct peroxisome proliferatoractivated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 279:34411-34420.
32. Matsusue K, Miyoshi A, Yamano S, and Gonzalez FJ (2006) Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. Mol Cell Endocrinol 256:23-33.
33. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154:799-814.
34. Moreno JJ (2009) New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochem Pharmacol 77:1-10.
35. Müller R, Kömhoff M, Peters JM, and Müller- Brüsselbach S (2008a) A Role for PPARbeta/delta in tumor stroma and tumorigenesis. PPAR Res 2008:534294.
36. Müller R, Rieck M, and Müller-Brüsselbach S (2008b) Regulation of Cell Proliferation and Differentiation by PPARbeta/delta. PPAR Res 2008:614852.
37. Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, Keil B, Klose KJ, Moll R, Burdick AD, et al. (2007) Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J 26:3686-3698.
38. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, and Desvergne B (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 26:3266-3281.
39. Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93:229-240.
40. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, and Peters JM (2006) The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 90:269-295.
41. Peters JM and Gonzalez FJ (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta 1796:230-241.
42. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, and Gonzalez FJ (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor beta(delta). Mol Cell Biol 20:5119-5128.
43. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, and Honn KV (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 26:503-524.
44. Rieck M, Meissner W, Ries S, Müller-Brüsselbach S, and Müller R (2008) Ligandmediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol Pharmacol 74:1269-1277.
45. Romano M (2006) Lipid mediators: lipoxin and aspirin-triggered 15-epi-lipoxins. Inflamm Allergy Drug Targets 5:81-90.
46. Schild RL, Schaiff WT, Carlson MG, Cronbach EJ, Nelson DM, and Sadovsky Y (2002) The activity of PPAR gamma in primary human trophoblasts is enhanced by oxidized lipids. J Clin Endocrinol Metab 87:1105-1110.
47. Schug TT, Berry DC, Shaw NS, Travis SN, and Noy N (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129:723-733.
48. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, et al. (2001) 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61:497-503.
49. Shi Y, Hon M, and Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A 99:2613-2618.
50. Stafslien DK, Vedvik KL, De Rosier T, and Ozers MS (2007) Analysis of liganddependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay. Mol Cell Endocrinol 264:82-89.
51. Thuillier P, Brash AR, Kehrer JP, Stimmel JB, Leesnitzer LM, Yang P, Newman RA, and Fischer SM (2002) Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem J 366:901-910.
52. Titos E, Chiang N, Serhan CN, Romano M, Gaya J, Pueyo G, and Clària J (1999) Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). Am J Physiol 277:C870-C877.
53. Umesono K, Murakami KK, Thompson CC, and Evans RM (1991) Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65:1255-1266.
54. van Dijk AP, McCafferty DM, Wilson JH, and Zijlstra FJ (1993) 15-Hydroxyeicosatetraenoic acid has minor anti-inflammatory properties in colitis. Agents Actions 38 Spec No:C120-C121.
55. Varnat F, Heggeler BB, Grisel P, Boucard N, Corthésy-Theulaz I, Wahli W, and Desvergne B (2006) PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 131:538-553.
56. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA, and Pestell RG (2001) Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 21:3057-3070.
57. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, and DuBois RN (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6:285-295.
58. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403.
59. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, and Lazar MA (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270:23975-23983.
60. Yu S and Reddy JK (2007) Transcription coactivators for peroxisome proliferatoractivated receptors. Biochim Biophys Acta 1771:936-951.
61. Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73.
62. Zoete V, Grosdidier A, and Michielin O (2007) Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771:915-925.